LONDON (AP):
Britain granted the conditional authorisation on Thursday to the first pill shown to successfully treat COVID-19 so far. It also is the first country to OK the treatment from drugmaker Merck, although it wasn’t immediately clear how quickly the pill would be available.
The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe diseases, such as obesity or heart disease. Patients with mild to moderate COVID-19 would take four pills of the drug, known as molnupiravir, twice a day for five days.
An antiviral pill that reduces symptoms and speeds recovery could prove groundbreaking, easing caseloads on hospitals and helping to curb outbreaks in poorer countries with fragile health systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.
Molnupiravir is also pending review with regulators in the US, the European Union and elsewhere. The US Food and Drug Administration announced last month that it would convene a panel of independent experts to scrutinise the pill’s safety and effectiveness in late November.